Avance Clinical CEO Talks with SCRIP about US Biotech Sector "Green Shoots" and a New CRO Report
(read the full article here)
- (read the full article here)
Avance Clinical CEO, Yvonne Lungershausen was interviewed by SCRIP Intelligence about the current biotech financial and drug development climate in the US and signs of growth. - Investors are really being super cautious about where they're investing and relatively, there's not a high-risk appetite," Lungershausen said to SCRIP in the interview.
- SCRIP Intelligence noted that Avance Clinical presented at JPM and Biotech Showcase a new analysis by market research leader, Frost & Sullivan on the biotech sector and the challenges they have finding the right fit or size CRO (See report here).
- For more information about the benefits of running your next study with Avance Clinical contact us: [email protected]